Restricted accessResearch articleFirst published online 2023-12
Chemical Complementarity of Tumor Resident,Adaptive Immune Receptor CDR3s and Previously Defined Hepatitis C Virus Epitopes Correlates with Improved Outcomes in Hepatocellular Carcinoma
To better understand how adaptive immune receptors (IRs) in hepatocellular carcinoma (HCC) microenvironments are related to disease outcomes, we employed a chemical complementarity scoring algorithm to quantify electrostatic complementarity between HCC tumor TRB or IGH complementarity-determining region 3 (CDR3) amino acid (AA) sequences and previously characterized hepatitis C virus (HCV) epitopes. High electrostatic complementarity between HCC-resident CDR3s and 12 HCV epitopes was associated with greater survival probabilities, as indicated by two distinct HCC IR CDR3 datasets. Two of the HCV epitopes, HCV*71871 (TRB) and HCV*13458 (IGH), were also determined to represent significantly larger electrostatic CDR3-HCV epitope complementarity in HCV-positive HCC cases, compared with HCV-negative HCC cases, with the CDR3s representing yet a third, independent HCC dataset. Overall, the results indicated the utility of CDR3 AA sequences as biomarkers for HCC patient stratification and as potential guides for the development of therapeutic reagents.
Get full access to this article
View all access options for this article.
References
1.
ArturoJF, ChobrutskiyBI, YeagleyM, et al.Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates. Cell Mol Immunol, 2019; 17(7):776–778; doi: 10.1038/s41423-019-0328-8
2.
AxleyP, AhmedZ, RaviS, et al.Hepatitis C virus and hepatocellular carcinoma: A narrative review. J Clin Transl Hepatol, 2018; 6(1):79–84; doi: 10.14218/JCTH.2017.00067
3.
BianY, LiQ, LiQ, et al.Silencing of BRF2 inhibits the growth and metastasis of lung cancer cells. Mol Med Rep, 2020; 22(3):1767–1774; doi: 10.3892/mmr.2020.11285
4.
BrownSD, RaeburnLA, HoltRA. Profiling tissue-resident T cell repertoires by RNA sequencing. Genome Med, 2015; 7(1):125; doi: 10.1186/s13073-015-0248-x
5.
CabarcasS, JacobJ, VerasI, et al.Differential expression of the TFIIIB subunits Brf1 and Brf2 in cancer cells. BMC Mol Biol, 2008; 9:74; doi: 10.1186/1471-2199-9-74
6.
CabarcasS, SchrammL. RNA polymerase III transcription in cancer: The BRF2 connection. Mol Cancer, 2011; 10:47; doi: 10.1186/1476-4598-10-47
7.
CeramiE, GaoJ, DogrusozU, et al.The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov, 2012; 2(5):401–404; doi: 10.1158/2159-8290.CD-12-0095
8.
ChangJH, XuBW, ShenD, et al.BRF2 is mediated by microRNA-409-3p and promotes invasion and metastasis of HCC through the Wnt/beta-catenin pathway. Cancer Cell Int, 2023; 23(1):46; doi: 10.1186/s12935-023-02893-y
9.
ChobrutskiyBI, ChobrutskiyA, ZamanS, et al.High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer. Mol Immunol, 2021; 135:247–253; doi: 10.1016/j.molimm.2021.02.026
10.
ChobrutskiyBI, YeagleyM, DivineyA, et al.A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: Multi-cancer analyses of associated survival rates. Immunology, 2020a;159(4):373–383; doi: 10.1111/imm.13165
11.
ChobrutskiyBI, YeagleyM, TippingP, et al.Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. Oncogene, 2020b;39(8):1773–1783; doi: 10.1038/s41388-019-1101-2
12.
ChobrutskiyBI, ZamanS, DivineyA, et al.T-cell receptor-alpha CDR3 domain chemical features correlate with survival rates in bladder cancer. J Cancer Res Clin Oncol, 2019; 145(3):615–623; doi: 10.1007/s00432-018-2815-1
13.
ChobrutskiyBI, ZamanS, TongWL, et al.Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade. J Neurooncol, 2018; 140(3):697–704; doi: 10.1007/s11060-018-03001-1
14.
CrispeIN, GiannandreaM, KleinI, et al.Cellular and molecular mechanisms of liver tolerance. Immunol Rev, 2006; 213:101–118; doi: 10.1111/j.1600-065X.2006.00435.x
15.
DanecekP, BonfieldJK, LiddleJ, et al.Twelve years of SAMtools and BCFtools. Gigascience, 2021; 10(2):giab008; doi: 10.1093/gigascience/giab008
16.
de MartelC, Maucort-BoulchD, PlummerM, et al.World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology, 2015; 62(4):1190–1200; doi: 10.1002/hep.27969
17.
Di BisceglieAM. Hepatitis C and hepatocellular carcinoma. Hepatology, 1997; 26(3 Suppl 1):34S–38S; doi: 10.1002/hep.510260706
18.
EakinsRA, ChobrutskiyA, TeerJK, et al.Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity. Mol Immunol, 2022; 150:58–66; doi: 10.1016/j.molimm.2022.08.001
19.
Ferrall-FairbanksMC, ChakiryanNH, ChobrutskiyBI, et al.Quantification of T- and B-cell immune receptor distribution diversity characterizes immune cell infiltration and lymphocyte heterogeneity in clear cell renal cell carcinoma. Cancer Res, 2022; 82(5):929–942; doi: 10.1158/0008-5472.CAN-21-1747
20.
GaoH, LiK, TuH, et al.Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res, 2014; 20(24):6418–6428; doi: 10.1158/1078-0432.CCR-14-1170
21.
GaoJ, AksoyBA, DogrusozU, et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal, 2013; 6(269):pl1; doi: 10.1126/scisignal.2004088
22.
GarciaMJ, PoleJC, ChinSF, et al.A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes. Oncogene, 2005; 24(33):5235–5245; doi: 10.1038/sj.onc.1208741
23.
GillTR, SamyMD, ButlerSN, et al.Detection of productively rearranged TcR-alpha V-J sequences in TCGA exome files: Implications for tumor immunoscoring and recovery of antitumor T-cells. Cancer Inform, 2016; 15:23–28; doi: 10.4137/CIN.S35784
HudaTI, DiazMJ, GozlanEC, et al.Immunogenomics parameters for patient stratification in Alzheimer's disease. J Alzheimers Dis, 2022; 88(2):619–629; doi: 10.3233/JAD-220119
26.
JiangZ, JiangX, ChenS, et al.Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. Front Immunol, 2016; 7:690; doi: 10.3389/fimmu.2016.00690
27.
LiB, LiT, WangB, et al.Ultrasensitive detection of TCR hypervariable-region sequences in solid-tissue RNA-seq data. Nat Genet, 2017; 49(4):482–483; doi: 10.1038/ng.3820
28.
LockwoodWW, ChariR, CoeBP, et al.Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med, 2010; 7(7):e1000315; doi: 10.1371/journal.pmed.1000315
29.
MadhaniHD, BordonneR, GuthrieC. Multiple roles for U6 snRNA in the splicing pathway. Genes Dev, 1990; 4(12B):2264–2277; doi: 10.1101/gad.4.12b.2264
30.
ManorO, SegalE. Predicting disease risk using bootstrap ranking and classification algorithms. PLoS Comput Biol, 2013; 9(8):e1003200; doi: 10.1371/journal.pcbi.1003200
31.
MauroJA, BlanckG. Functionally distinct gene classes as bigger or smaller transcription factor traps: A possible stochastic component to sequential gene expression programs in cancer. Gene, 2014; 536(2):398–406; doi: 10.1016/j.gene.2013.11.013
32.
MelchorL, GarciaMJ, HonradoE, et al.Genomic analysis of the 8p11–12 amplicon in familial breast cancer. Int J Cancer J Int Cancer, 2007; 120(3):714–717; doi: 10.1002/ijc.22354
33.
PatelAR, PatelDN, TuYN, et al.Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: Evidence for outcome mitigation with corticosteroid treatments. J Biomol Struct Dyn, 2023; 41(10):4632–4640; doi: 10.1080/07391102.2022.2070546
34.
PatelDN, YeagleyM, ArturoJF, et al.A comparison of immune receptor recombination databases sourced from tumour exome or RNAseq files: Verifications of immunological distinctions between primary and metastatic melanoma. Int J Immunogenet, 2021; 48(5):409–418; doi: 10.1111/iji.12550
35.
QuHQ, TienM, PolychronakosC. Statistical significance in genetic association studies. Clin Invest Med, 2010; 33(5):E266–E270; doi: 10.25011/cim.v33i5.14351
36.
RochigneuxP, ChanezB, De RauglaudreB, et al.Adoptive cell therapy in hepatocellular carcinoma: Biological rationale and first results in early phase clinical trials. Cancers, 2021; 13(2):271; doi: 10.3390/cancers13020271
37.
SangroB, SarobeP, Hervas-StubbsS, et al.Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2021; 18(8):525–543; doi: 10.1038/s41575-021-00438-0
38.
SchrammL, HernandezN. Recruitment of RNA polymerase III to its target promoters. Genes Dev, 2002; 16(20):2593–2620; doi: 10.1101/gad.1018902
39.
SiegelRL, MillerKD, FuchsHE, et al.Cancer statistics, 2022. CA Cancer J Clin, 2022; 72(1):7–33; doi: 10.3322/caac.21708
40.
SpearTT, CallenderGG, RoszkowskiJJ, et al.TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother, 2016; 65(3):293–304; doi: 10.1007/s00262-016-1800-2
41.
SungH, FerlayJ, SiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71(3):209–249; doi: 10.3322/caac.21660
42.
ThorssonV, GibbsDL, BrownSD, et al.The immune landscape of cancer. Immunity, 2018; 48(4):812–830 e814; doi: 10.1016/j.immuni.2018.03.023
43.
TongWL, TuYN, SamyMD, et al.Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer. Hum Vaccines Immunother, 2017; 13(3):501–506; doi: 10.1080/21645515.2016.1246095
44.
TuYN, TongWL, SamyMD, et al.Assessing microenvironment immunogenicity using tumor specimen exomes: Co-detection of TcR-alpha/beta V(D)J recombinations correlates with PD-1 expression. Int J Cancer J Int Cancer, 2017; 140(11):2568–2576; doi: 10.1002/ijc.30675
45.
WhiteRJ. RNA polymerase III transcription and cancer. Oncogene, 2004; 23(18):3208–3216; doi: 10.1038/sj.onc.1207547
46.
WhiteRJ. RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol, 2005; 6(1):69–78; doi: 10.1038/nrm1551
47.
XuJL, DavisMM. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity, 2000; 13(1):37–45; doi: 10.1016/s1074-7613(00)00006-6
48.
YangJ, PanG, GuanL, et al.The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels. Cancer Med, 2022; 11(5):1357–1370; doi: 10.1002/cam4.4530
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
